Skip to main content
Veterinary Medicines

Bacolam Injectable (100 mg + 250000 IU)/ml Zawiesina do wstrzykiwań

Authorised
  • Amoxicillin trihydrate
  • COLISTIN SULFATE

Product identification

Medicine name:
Bacolam Injectable (100 mg + 250000 IU)/ml Zawiesina do wstrzykiwań
Active substance:
  • Amoxicillin trihydrate
  • COLISTIN SULFATE
Target species:
  • Pig
  • Cattle
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Amoxicillin trihydrate
    114.80
    milligram(s)
    /
    1.00
    millilitre(s)
  • COLISTIN SULFATE
    250000.00
    international unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        10
        day
    • Cattle
      • Meat and offal
        24
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01RA01
Authorisation status:
  • Valid
Authorised in:
  • Poland
Available in:
  • Poland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Office For Registration Of Medicinal Products Medical Devices And Biocidal Products
Authorisation number:
  • 1098
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."